# A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)

> **NCT00497497** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** cetuximab
- **DRUG:** FOLFIRI regimen
- **DRUG:** irinotecan
- **DRUG:** PRO95780

## Key facts

- **NCT ID:** NCT00497497
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00497497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00497497, "A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00497497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*